Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...
Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.
The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...
It might take a while longer, but Pfizer is on the path to recovery. Is 2026 the year Pfizer (NYSE: PFE) finally turns things ...
First-ever fentanyl overdose prevention vaccine could save thousands of lives annually, with human trials beginning early ...
With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming ...
CYB003/CYB004 clinical catalysts into 2026, $248M cash runway, equity raises risk, valuation optionality. Click for this CYBN ...
In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, ...
FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...
Drug major Alkem Laboratories Limited has received a key regulatory clearance from the Subject Expert Committee (SEC) ...
Abivax skyrocketed by 1,742.28 percent in 2025, as investor sentiment was primarily bolstered by a series of upbeat analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback